Why Pacira Pharmaceuticals Shares Are Crashing 15% Today
Pacira Pharmaceuticals (NASDAQ: PCRX) shares are down 15% at 12:00 p.m. EDT today following word that its pain medicine Exparel didn't perform as well as hoped in key phase 3 studies.
Pacira Pharmaceuticals already markets the surgical-pain medicine Exparel, and its sales have been growing quickly as doctors embrace ways to control pain that may reduce a patient's need for rescue pain medications, like opioids.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Pacira Pharmaceuticals Aktie
?
0,00 %
Mehrere Buy-Einschätzungen geben Pacira Pharmaceuticals den Vorteil, ohne Sell-Einschätzungen.
Mit einem Kursziel von 27 € für Pacira Pharmaceuticals könnte der aktuelle Kurs von 20.2 € um mehr als 20% steigen.
